MGUS — Monoclonal Gammopathy of Undetermined Significance

Distinguishing MGUS from myeloma and Waldenström macroglobulinemia, Mayo Clinic risk stratification, surveillance intervals, and the risk of progression

Key Points

• MGUS is defined by a serum M-protein <3 g/dL, bone marrow plasma cells <10%, and absence of CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions) or light chain–mediated end-organ damage — it is an incidental finding in 3.2% of adults >50 and 5.3% >70.
• The Mayo Clinic risk stratification model identifies three risk factors for progression: M-protein ≥1.5 g/dL, non-IgG subtype (IgA or IgM MGUS), and abnormal serum free light chain (kFLC) ratio (<0.26 or >1.65) — cumulative 20-year progression risk ranges from 5% (0 risk factors) to 58% (all 3 risk factors).
• The overall risk of MGUS progressing to myeloma, Waldenström macroglobulinemia, AL amyloidosis, or another lymphoplasmacytic disorder is approximately 1%/year — making long-term but not intensive surveillance the appropriate management.
• IgM MGUS requires separate evaluation — it precedes Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), not multiple myeloma, and has different laboratory and bone marrow features (MYD88 L265P mutation in >90% of WM).
• Light chain (LC) MGUS (abnormal kFLC ratio without intact immunoglobulin M-protein on serum SPEP) carries a risk of progression to AL amyloidosis and light chain myeloma — requires urine protein electrophoresis and 24-hour urine protein quantification.
• No treatment is indicated for MGUS — randomized trials of early intervention with lenalidomide and other agents have not demonstrated a survival benefit over surveillance, and early treatment carries unacceptable toxicity in an otherwise asymptomatic population.

Definition, Epidemiology, and Classification

**Diagnostic criteria for MGUS (IMWG 2014):** 1. Serum monoclonal protein (M-protein) 11 mg/dL), renal insufficiency (creatinine >2 mg/dL or eGFR 1 focal lesion on MRI ≥5 mm (these criteria define smoldering myeloma high-risk, not MGUS) - Evidence of AL amyloidosis, POEMS, or other plasma cell–related end-organ damage **Classification by immunoglobulin subtype:** *Non-IgM MGUS (IgG, IgA, IgE, IgD):* - The most common form — ~70% of all MGUS - IgG MGUS: most common (65% of MGUS); risk of progression to IgG multiple myeloma - IgA MGUS: ~14%; slightly higher risk of progression than IgG - IgD,…

Risk Stratification and Surveillance

**Mayo Clinic MGUS Risk Stratification (Kyle & Rajkumar, NEJM 2002):** The standard prognostic model, validated in prospective population studies: | Risk Factors Present | Risk Group | 20-Year Progression Risk | |---|---|---| | 0 | Low | ~5% | | 1 | Low-intermediate | ~21% | | 2 | Intermediate-high | ~37% | | 3 | High | ~58% | Three risk factors: 1. **M-protein ≥1.5 g/dL** (larger clones are closer to myeloma threshold) 2. **Non-IgG isotype** (IgA, IgM, or other — IgA MGUS has slightly higher inherent progression risk) 3. **Abnormal serum free light chain ratio** (kFLC 1.65 — reflects…

Clinical Complications and Management Considerations

**No treatment for MGUS — surveillance only:** The ECOG E3A06 randomized trial of lenalidomide vs. placebo in high-risk MGUS was stopped early due to insufficient evidence of benefit and excess toxicity in an asymptomatic population. No preventive therapy has demonstrated a benefit in overall survival. **MGUS-associated neuropathy:** Approximately 5–10% of unexplained peripheral neuropathy in adults has an associated M-protein — the M-protein can directly mediate nerve damage: - Anti-MAG (myelin-associated glycoprotein) IgM neuropathy: distal, symmetric, predominantly sensory; demyelinating…